Sangamo Therapeutics

News

Sangamo cues up Fabry gene therapy filing on STAAR data

Sangamo plans to file for approval of its gene therapy for Fabry disease next year, but a launch could depend on finding a commercial partner.

News

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.

News

Pfizer ducks out of Sangamo haemophilia A alliance

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.

News

Can Pfizer, Sangamo energise haemophilia A gene therapy?

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow.

News

Sangamo sheds staff once again in another retreat

Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused

News

Double blow for Sangamo as Novartis, Biogen exit deals

The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.

Sangamo cues up Fabry gene therapy filing on STAAR data

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

Pfizer ducks out of Sangamo haemophilia A alliance

Can Pfizer, Sangamo energise haemophilia A gene therapy?

Sangamo sheds staff once again in another retreat

Double blow for Sangamo as Novartis, Biogen exit deals

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Sangamo Therapeutics

Editor's Picks